Published 2 months ago

FDA approves Merck's drug for rare, deadly lung condition

Summary by Ground News

Merck bought the company developing the drug, Acceleron Pharma, for $11.5 billion in 2021. Winrevair will be the first drug to treat the underlying cause of the disease instead of just managing its symptoms. About 40,000 people in the U.S. live with the disease.

0 Articles

All

Left

Center

Right

CNBC

FDA approves Merck's drug for rare, deadly lung condition

The Food and Drug Administration on Tuesday approved a drug from Merck designed to treat a progressive and life-threatening lung condition in a win for both the...

2 months ago·United States

Read Full Article

Forbes

FDA Approves Merck’s New Drug For A Rare Lung Disease

The pharmaceutical giant’s new treatment, sotatercept, showed significant benefits for the thousands of patients suffering from pulmonary arterial hypertension in clinical trials.

2 months ago·United States

Read Full Article

Quartz

The FDA has approved Merck's drug to treat a rare, deadly lung disease

The Food and Drug Administration has approved pharma giant Merck’s drug to treat a rare and sometimes deadly lung condition, Merck and the agency said Tuesday.Read more...

2 months ago·United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.